-
公开(公告)号:US20110081292A1
公开(公告)日:2011-04-07
申请号:US12944432
申请日:2010-11-11
申请人: Francisco Sanchez-Madrid , Carlos-Martinez Alonso , David Sancho Madrid , Pablo Engel Rocamora , Enric Esplugues Artola , Javier Vega Ramos , Pilar Lauzurica Gómez
发明人: Francisco Sanchez-Madrid , Carlos-Martinez Alonso , David Sancho Madrid , Pablo Engel Rocamora , Enric Esplugues Artola , Javier Vega Ramos , Pilar Lauzurica Gómez
IPC分类号: A61K51/10 , A61K39/395 , A61P31/14
CPC分类号: C07K16/2851 , A61K2039/505 , C07K2317/76
摘要: Disclosed are methods of treating viral hepatitis including administering an effective amount of an early activation molecule agonist, antagonist or depletor, to the subject. Human monoclonal antibodies specific to the early activation molecules, and methods of use, are also disclosed.
摘要翻译: 公开了治疗病毒性肝炎的方法,包括向受试者施用有效量的早期活化分子激动剂,拮抗剂或deputor。 还公开了对早期活化分子特异性的人单克隆抗体及其使用方法。
-
公开(公告)号:US07867475B2
公开(公告)日:2011-01-11
申请号:US10770639
申请日:2004-02-02
申请人: Francisco Sanchez-Madrid , Carlos Martinez Alonso , David Sancho Madrid , Pablo Engel Rocamora , Enric Esplugues Artola , Javier Vega Ramos , Pilar Lauzurica Gómez
发明人: Francisco Sanchez-Madrid , Carlos Martinez Alonso , David Sancho Madrid , Pablo Engel Rocamora , Enric Esplugues Artola , Javier Vega Ramos , Pilar Lauzurica Gómez
IPC分类号: A61K51/00
CPC分类号: C07K16/2851 , A61K2039/505 , C07K2317/76
摘要: Disclosed are methods of treating subjects having disorders or conditions characterized by an unwanted immune response including administering an effective amount of an early activation molecule agonist, antagonist or depletor, to the subject. Human monoclonal antibodies specific to the early activation molecules, and methods of use, are also disclosed.
摘要翻译: 公开了治疗具有由不想要的免疫应答表征的疾病或病症的受试者的方法,包括向受试者施用有效量的早期活化分子激动剂,拮抗剂或抑制剂。 还公开了对早期活化分子特异性的人单克隆抗体及其使用方法。
-
公开(公告)号:US08182816B2
公开(公告)日:2012-05-22
申请号:US12944338
申请日:2010-11-11
申请人: Francisco Sanchez-Madrid , Carlos-Martinez Alonso , David Sancho Madrid , Pablo Engel Rocamora , Enric Esplugues Artola , Javier Vega Ramos , Pilar Lauzurica Gomez
发明人: Francisco Sanchez-Madrid , Carlos-Martinez Alonso , David Sancho Madrid , Pablo Engel Rocamora , Enric Esplugues Artola , Javier Vega Ramos , Pilar Lauzurica Gomez
IPC分类号: A61K39/395
CPC分类号: C07K16/2851 , A61K2039/505 , C07K2317/76
摘要: Disclosed are methods of treating subjects having cancers including administering an effective amount of an early activation molecule agonist, antagonist or depletor, to the subject. Human monoclonal antibodies specific to the early activation molecules, and methods of use, are also disclosed.
摘要翻译: 公开了治疗患有癌症的受试者的方法,包括向受试者施用有效量的早期活化分子激动剂,拮抗剂或抑制剂。 还公开了对早期活化分子特异性的人单克隆抗体及其使用方法。
-
公开(公告)号:US08580266B2
公开(公告)日:2013-11-12
申请号:US12669940
申请日:2008-07-21
申请人: David Sancho-Madrid , Oliver Schulz , Neil Charles Rogers , Caetano Reis E Sousa , Olivier Pierre Joffre , Daniel Pennington
发明人: David Sancho-Madrid , Oliver Schulz , Neil Charles Rogers , Caetano Reis E Sousa , Olivier Pierre Joffre , Daniel Pennington
IPC分类号: A61K39/395 , A61K39/00
CPC分类号: A61K47/48415 , A61K39/0005 , A61K39/0011 , A61K47/6811 , A61K2039/507 , A61K2039/57 , A61K2039/6056 , C07K16/2851 , C07K16/2878 , C07K2317/55 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2319/33
摘要: The invention relates to the regulation of the immune system, and in particular to the finding that the CLEC9a molecule is a marker for dendritic cells which are capable of cross-presenting extracellular antigens via the MHC class I pathway. This makes them particularly suitable for generation of cytotoxic T lymphocyte responses. Materials and methods are provided both for the induction of immune responses against target antigens, and for the inhibition or suppression of undesirable immune responses in which these cells are involved.
-
公开(公告)号:US20100221265A1
公开(公告)日:2010-09-02
申请号:US12669940
申请日:2008-07-21
申请人: David Sancho-Madrid , Oliver Schulz , Neil Charles Rogers , Caetano Reis E. Sousa , Olivier Pierre Joffre , Daniel Pennington
发明人: David Sancho-Madrid , Oliver Schulz , Neil Charles Rogers , Caetano Reis E. Sousa , Olivier Pierre Joffre , Daniel Pennington
IPC分类号: A61K39/395 , C12N5/0784 , A61K39/00 , C07K14/00 , C07K16/00 , A61K31/7052 , A61K38/43 , C12N9/00 , G01N33/53 , C12N5/0783 , A61K35/12 , A61P37/00
CPC分类号: A61K47/48415 , A61K39/0005 , A61K39/0011 , A61K47/6811 , A61K2039/507 , A61K2039/57 , A61K2039/6056 , C07K16/2851 , C07K16/2878 , C07K2317/55 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2319/33
摘要: The invention relates to the regulation of the immune system, and in particular to the finding that the CLEC9a molecule is a marker for dendritic cells which are capable of cross-presenting extracellular antigens via the MHC class I pathway. This makes them particularly suitable for generation of cytotoxic T lymphocyte responses. Materials and methods are provided both for the induction of immune responses against target antigens, and for the inhibition or suppression of undesirable immune responses in which these cells are involved.
摘要翻译: 本发明涉及免疫系统的调节,特别是关于CLEC9a分子是能够通过MHC I类途径交叉呈递细胞外抗原的树突状细胞的标记的发现。 这使得它们特别适合于产生细胞毒性T淋巴细胞应答。 提供材料和方法用于诱导针对靶抗原的免疫应答,以及用于抑制或抑制其中涉及这些细胞的不期望的免疫应答。
-
公开(公告)号:US20110165071A1
公开(公告)日:2011-07-07
申请号:US12944338
申请日:2010-11-11
申请人: Francisco Sanchez-Madrid , Carlos Martinez Alonso , David Sancho Madrid , Pablo Engel Rocamora , Enric Esplugues Artola , Javier Vega Ramos , Pilar Lauzurica Gómez
发明人: Francisco Sanchez-Madrid , Carlos Martinez Alonso , David Sancho Madrid , Pablo Engel Rocamora , Enric Esplugues Artola , Javier Vega Ramos , Pilar Lauzurica Gómez
IPC分类号: A61K39/395 , A61K51/00 , A61P35/00
CPC分类号: C07K16/2851 , A61K2039/505 , C07K2317/76
摘要: Disclosed are methods of treating subjects having cancers including administering an effective amount of an early activation molecule agonist, antagonist or depletor, to the subject. Human monoclonal antibodies specific to the early activation molecules, and methods of use, are also disclosed.
摘要翻译: 公开了治疗患有癌症的受试者的方法,包括向受试者施用有效量的早期活化分子激动剂,拮抗剂或抑制剂。 还公开了对早期活化分子特异性的人单克隆抗体及其使用方法。
-
-
-
-
-